Document Detail


First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
MedLine Citation:
PMID:  17442078     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A 26-year-old man presented to our clinic for advice on treatment options regarding cutaneous leishmaniasis (CL) with multiple lesions. The biopsy revealed Leishmania amastigotes; Leishmania major was identified by polymerase chain reaction (PCR).(11 )Leishmania serology (indirect immunofluorescence test) was positive at 1 : 160 (normal, < or = 1 : 40). Ten weeks earlier, the patient had spent a 1-week biking holiday in central Tunisia. Two weeks after returning to Germany, he noticed the flaring up of multiple insect bites (> 40) contracted in Tunisia on both arms. The lesions increased in size and axillary lymph node enlargement occurred. Some of the nodular lesions disappeared spontaneously and some increased in size and showed central ulceration. When we first saw the patient, he had six lesions on his right arm and one on his left arm. The largest lesion was on the dorsum of the right hand (Fig. 1) and showed an indurated edge and central ulceration. Before starting systemic treatment, the patient decided to wait a few weeks in case spontaneous improvement occurred. However, 8 weeks later, the ulceration had further increased in size (Fig. 2) from a diameter of 2 cm initially to a diameter of 5 cm. Regional lymphatic spread with palpable nodules along the adjacent lymphatic vessel had occurred. With the patient's informed consent, treatment with oral miltefosine, according to his body weight of 96 kg, was started at 50 mg three times daily for 28 days. The treatment was well tolerated without any subjective side-effects reported. Liver enzymes, serum creatinine, and urea were monitored during treatment. There was a mild increase in liver enzymes during the third week of treatment: aspartate aminotransferase (AST), 49 U/L (normal, < 35 U/L); alanine aminotransferase (ALT), 107 U/L (normal, < 45 U/L); this resolved spontaneously. Ten days after completion of treatment, the rolled edge had disappeared and the central ulcer had almost healed (Fig. 3). Figure 4 shows the lesion 5 months after completion of treatment.
Authors:
Marija Stojkovic; Thomas Junghanss; Eric Krause; Robert N Davidson
Related Documents :
1099898 - Antacid vs placebo in hospitalized gastric ulcer patients: a controlled therapeutic study.
19376798 - Four layer bandage compared with short stretch bandage for venous leg ulcers: systemati...
12405248 - Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative co...
1395848 - Full-valve annuloplasty in treatment of primary deep venous valvular incompetence of th...
18297368 - Outcome in unilateral or bilateral ddh treated with one-stage combined procedure.
24140168 - The effect of positive balance on the outcomes of critically ill noncardiac postsurgica...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  International journal of dermatology     Volume:  46     ISSN:  0011-9059     ISO Abbreviation:  Int. J. Dermatol.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-19     Completed Date:  2007-06-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0243704     Medline TA:  Int J Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  385-7     Citation Subset:  IM    
Affiliation:
Section of Clinical Tropical Medicine, Heidelberg University Hospital, Heidelberg, and General Practice, Dreisamstr. 11, Freiburg, Germany. marija.stojkovic@med.uni-heidelberg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Animals
Antiprotozoal Agents / administration & dosage,  therapeutic use*
DNA, Protozoan / analysis
Diagnosis, Differential
Humans
Leishmania major* / genetics,  isolation & purification
Leishmaniasis, Cutaneous / diagnosis*,  drug therapy*,  pathology
Male
Phosphorylcholine / administration & dosage,  analogs & derivatives*,  therapeutic use
Polymerase Chain Reaction
Chemical
Reg. No./Substance:
0/Antiprotozoal Agents; 0/DNA, Protozoan; 107-73-3/Phosphorylcholine; 58066-85-6/miltefosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The emergence of mucormycosis as an important opportunistic fungal infection: five cases presenting ...
Next Document:  Mycotic cysts: report of 21 cases including eight pheomycotic cysts from Saudi Arabia.